Phenotypic Screening for Inhibitors of a Mutant Thrombopoietin Receptor.
(2018) Methods in molecular biology (Clifton, N.J.) — Vol. 1787, p. 53-66 (2018)
Files
No attached file found for this publication.
Details
- Authors
- Abstract
- An inhibitor for the thrombopoietin receptor (TpoR) would be more specific for the treatment of myeloproliferative neoplasms (MPNs) due to constitutively active mutant TpoR compared to the current treatment approach of inhibiting Janus kinase 2 (JAK2). We describe a cell-based high-throughput phenotypic screening approach to identify inhibitors for constitutively active mutant TpoR. A stepwise elimination process is used to differentiate generally cytotoxic compounds from compounds that specifically inhibit growth of cells expressing wild-type TpoR and/or mutant TpoR. We have systematically optimized the phenotypic screening assay and documented in this chapter critical parameters for a successful phenotypic screen, such as cell growth and seeding optimization, plate reproducibility and uniformity studies, and an assay robustness analysis with a pilot screen.
- Affiliations
Citations
Ngo, A., Koay, A., Pecquet, C., Diaconu, C. C., Jenkins, D. A., Shiau, A. K., Constantinescu, S., & Choong, M. L. (2018). Phenotypic Screening for Inhibitors of a Mutant Thrombopoietin Receptor. Methods in molecular biology (Clifton, N.J.), 1787, 53-66. https://doi.org/10.1007/978-1-4939-7847-2_4 (Original work published 2018)